News
Novel Vaccine Shows Promise in Pancreatic Cancer
An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive survival outcomes in patients with resected pancreatic and colorectal cancers, according to final results from the phase I AMPLIFY-201 trial.
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.
Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine ...
The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...
Black and Hispanic people are more likely to be diagnosed with pancreatic cancer and more likely to die from it. Now, one drug may help fix this.
Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in treatment for cancers, rare disease and more.
In fact, only 10 per cent of patients are diagnosed in time for life-saving surgery. But a potential vaccine is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback